This phase 1b trial is combining two different biological injections (a talimogene laherparepvec injection into the liver and an atezolizumab injection into the vein) in patients who have triple negative breast cancer or colorectal cancer that has spread to the liver.
This trial is treating multiple types of cancer including triple negative breast cancer and colorectal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Up to 36 subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
The goal of this study is to evaluate the safety of intrahepatic injection of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
Patients will receive Talimogene laherparepvec via intralesional injection (directly into the liver) on Day one and every 21 days per protocol for a maximum on 12 cycles. Atezolizumab will also be given to patients via by intravenous injection on Day one and every 21 days per protocol.
Recruiting Hospitals Read More